Utah’s new law does not legalize psychedelic therapy. It authorizes a tightly regulated clinical study at the Huntsman Mental Health Institute for veterans with treatment-resistant PTSD.
On March 19, Gov. Spencer Cox signed H.B. 390, the Veterans PTSD Clinical Research Amendments, into law. The measure authorizes the Huntsman Mental Health Institute at the University of Utah to conduct a clinical study on psychedelic-assisted therapy for veterans with treatment-resistant PTSD. Cox’s office included H.B. 390 in a batch of 74 bills signed that day.
That makes Utah notable for a specific reason. This is not a decriminalization bill. It does not create a statewide access model. Utah chose a narrower path: state-authorized clinical research inside a mainstream medical institution, with veterans at the center.
Utah’s approach lands somewhere between Oregon and Colorado’s broader state-level experiments and the federal setback that followed the FDA’s rejection of Lykos’ MDMA application: narrower than a public access model, but more ambitious than waiting for Washington to move first.
H.B. 390 is written as a clinical research law, not a general access law. The bill defines an eligible veteran as a veteran with treatment-resistant PTSD. It authorizes research into the safety and feasibility of psychedelic-assisted therapy for that population, and it specifically names MDMA, psilocybin, and 5-methoxy-N,N-dimethyltryptamine, better known as 5-MeO-DMT, as qualifying investigational psychedelic drugs. The law also defines psychedelic-assisted therapy in clinical terms: administration of the drug in a controlled setting, paired with manualized, trauma-informed preparatory and integrative psychotherapy delivered by a qualified therapist.
That language shows how carefully Utah lawmakers framed the effort. The bill does not endorse broad consumer access. It authorizes a study. And not just any study. Before the clinical study can begin, Huntsman must operate under an FDA investigational new drug application, maintain DEA Schedule I research registration and any required state controlled-substance registration, and obtain Institutional Review Board approval.
The law also requires a detailed protocol. That includes study design, inclusion and exclusion criteria, follow-up schedules, informed consent procedures, participant safeguards, data security and privacy protections, drug source and dosing details, staffing and monitoring procedures, discharge and transportation rules, chain-of-custody and disposal procedures for controlled substances, emergency response planning, adverse event reporting, therapist licensure and qualification requirements, training and supervision plans, and a participant complaint and grievance process. This is not loose policy language. It is an attempt to build a highly structured medical research container around a politically sensitive area of treatment.
There is also a practical reason this bill moved. It is focused on veterans, and that gives lawmakers a narrower and more politically defensible case for action. The bill itself does not claim that the science is settled. It creates a path to gather more evidence under state-backed institutional oversight for a population with high rates of severe PTSD and a clear need for better options.
The funding picture is more limited than the headline might suggest. The enrolled bill itself states that there is no direct appropriation in H.B. 390. Instead, it says Huntsman must begin the study if legislative appropriations plus gifts, grants, or donations reach an amount the institute determines is sufficient to launch. Separate Utah legislative budget materials show a one-time approved amount of $1 million tied to “Veterans PTSD Clinical Research Amendments (H.B. 390)” at the University of Utah. Huntsman may also continue accepting gifts, grants, and donations to fund the study.
The governor’s signature is a real milestone, but not the end of the story. The next phase is operational. Huntsman still has to finalize the protocol, satisfy federal and state regulatory requirements, secure or manage sufficient funding, and build the staffing and clinical infrastructure needed to run the study. The law says the institute must begin by January 1, 2027 if the available funding is sufficient. If it is not, Huntsman can keep raising money and launch later once the threshold is met.
The law also includes reporting requirements. Huntsman must report progress to the Health and Human Services Interim Committee upon request and submit a final written report after the study concludes. That report must include safety and feasibility outcomes, along with any secondary or exploratory clinical outcomes. The clinical study provisions sunset on July 1, 2032.
For the psychedelic field, Utah’s move is worth watching because it points to a different route than ballot campaigns or broad legalization debates. H.B. 390 is narrow, institution-based, and built to survive political scrutiny. For states unwilling to move toward broader access, that model may prove easier to replicate.
Gov. Cox’s signature does not legalize psychedelic therapy in Utah. It creates a formal clinical research pathway for veterans with treatment-resistant PTSD inside a major medical institution, under federal research rules and state reporting requirements. It is a limited step, but a meaningful one.
